Kymera director exercises and sells 2,500 shares

Kymera Therapeutics director Pamela Esposito exercised options for 2,500 shares of Common Stock at an exercise price of $49.10 per share and sold all 2,500 shares the same day.

Accepted by SEC EDGAR 03/20/2026 - 06:30 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Kymera Therapeutics director Pamela Esposito exercised options for 2,500 shares of Common Stock at an exercise price of $49.10 per share and sold all 2,500 shares the same day. The sales were executed in three open-market transactions at weighted average prices of $77.71, $79.24 and $79.94 per share. These transactions were carried out under a pre-arranged Rule 10b5-1 trading plan dated September 17, 2025, meaning the trades were scheduled in advance rather than timed discretionarily.

Insider Trade Summary 10b5-1

Exercise and Sale: 2,500 shares ($75K approx. pre-tax spread)

Exercise and Sale 5 txns

Insider Esposito Pamela

Role Director

Sold 2,500 shs ($198K)

Approx. gross sale proceeds $198K

Approx. exercise cost $123K

Approx. pre-tax spread $75K

Share of Position Sold 100%

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy)	2,500	$0.00	$0.00
Exercise	Common Stock	2,500	$49.10	$123K
Sale	Common Stock	700	$77.7111	$54K
Sale	Common Stock	600	$79.2439	$48K
Sale	Common Stock	1,200	$79.9442	$96K

Holdings After Transaction: Stock Option (Right to Buy) — 0 contracts (Direct); Common Stock — 0 shares (Direct)

Holdings Before and After: Stock Option (Right to Buy), 2,500 to 0 contracts (Direct); Common Stock, 0 to 0 shares (Direct)

Other Insiders: 5 other insiders reported open-market sales of this stock in the 30 days up to this filing.

Footnotes (5)

1. F1. These transactions were effected pursuant to a Rule 10b5-1 trading plan dated September 17, 2025 adopted by the reporting person.
2. F2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $77.46 to $77.98, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
3. F3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $78.70 to $79.63, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
4. F4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $79.73 to $80.27, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
5. F5. The shares underlying this stock option are fully vested and exercisable.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Kymera Therapeutics (KYMR) director Pamela Esposito do in this Form 4?

Pamela Esposito exercised options for 2,500 Kymera Therapeutics shares at $49.10 and sold all 2,500 shares the same day in three open-market transactions at prices around the high-$70s, under a pre-arranged Rule 10b5-1 trading plan.

How many Kymera Therapeutics (KYMR) shares were sold and at what prices?

A total of 2,500 Kymera Therapeutics Common Stock shares were sold. The Form 4 reports three weighted average sale prices: $77.7111 for 700 shares, $79.2439 for 600 shares, and $79.9442 for 1,200 shares, all executed in multiple trades within narrow intraday price ranges.

Was the Kymera Therapeutics (KYMR) insider trading under a Rule 10b5-1 plan?

Yes. The Form 4 states that these transactions were effected under a Rule 10b5-1 trading plan dated September 17, 2025. Such plans schedule trades in advance, so execution timing reflects a preset plan rather than day-to-day trading decisions by the reporting person.

What type of derivative security did the Kymera Therapeutics (KYMR) director exercise?

The director exercised a Stock Option (Right to Buy) covering 2,500 Kymera Therapeutics Common Stock shares. The option had an exercise price of $49.10 per share and an expiration date of June 15, 2031, and the shares underlying the option were fully vested and exercisable.

What were Pamela Esposito’s holdings after these Kymera Therapeutics (KYMR) transactions?

For this reported block of transactions, the Form 4 shows 0 stock options remaining from the exercised grant and 0 Common Stock shares remaining from the 2,500 shares acquired and sold. All reported holdings here are direct, with no indirect ownership noted in the filing data.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Esposito Pamela

(Last) (First) (Middle)

C/O KYMERA THERAPEUTICS, INC.

500 NORTH BEACON STREET, 4TH FLOOR

(Street)

WATERTOWN MASSACHUSETTS 02472

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Kymera Therapeutics, Inc. [ KYMR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/20/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/20/2026		M(1)		2,500	A	$49.1	2,500	D
Common Stock	03/20/2026		S(1)		700	D	$77.7111(2)	1,800	D
Common Stock	03/20/2026		S(1)		600	D	$79.2439(3)	1,200	D
Common Stock	03/20/2026		S(1)		1,200	D	$79.9442(4)	0	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$49.1	03/20/2026		M(1)			2,500	(5)	06/15/2031	Common Stock	2,500	$0	0	D

Explanation of Responses:

1. These transactions were effected pursuant to a Rule 10b5-1 trading plan dated September 17, 2025 adopted by the reporting person.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $77.46 to $77.98, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $78.70 to $79.63, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $79.73 to $80.27, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

5. The shares underlying this stock option are fully vested and exercisable.

	/s/ Bruce Jacobs, as Attorney-in-Fact	03/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)